IKBIP

IKBIP (also called IKIP) is a p53-inducible transmembrane protein that functions as a negative regulator of NF-κB signaling by physically binding IKKα/β and blocking their association with NEMO, thereby suppressing IKK phosphorylation and downstream inflammatory responses; IKBIP-deficient mice exhibit exacerbated LPS-induced septic shock and DSS-induced colitis (PMID:31826938). Beyond its immune-regulatory role, IKBIP stabilizes CDK4 by preventing its ubiquitin-mediated proteasomal degradation, promoting G1/S cell-cycle progression in glioblastoma cells (PMID:36244542), and activates AKT and Wnt/β-catenin/EMT signaling to drive proliferation and invasion in glioma and esophageal squamous cell carcinoma (PMID:38914958, PMID:42004064). IKBIP expression is transcriptionally induced by p53 from a bidirectional promoter shared with APAF1 and by SP1 binding to its own promoter, and its overexpression promotes apoptosis in endothelial cells (PMID:15389287, PMID:42004064).

1. 2004 Medium

   Identification of IKIP as a p53-inducible proapoptotic gene sharing a bidirectional promoter with APAF1 established it as a stress-responsive effector within the p53 apoptotic network.

   Evidence Promoter mapping and X-irradiation of endothelial cells showing p53-dependent upregulation and overexpression-induced apoptosis

   PMID:15389287

   Open questions at the time

   • Endogenous proapoptotic mechanism and relevant protein interactions were not defined
   • Whether the bidirectional promoter coordinates IKIP and APAF1 functionally was not tested
   • No loss-of-function data provided
2. 2019 High

   Demonstration that IKIP binds IKKα/β and prevents their association with NEMO resolved its molecular mechanism as a negative regulator of NF-κB, explaining its role in restraining inflammatory responses in vivo.

   Evidence Reciprocal Co-IP for IKIP–IKKα/β interaction, IKIP-knockout macrophages and mice challenged with LPS, TNF-α, IL-1β, and in vivo septic shock and colitis models

   PMID:31826938

   Open questions at the time

   • Structural basis of IKIP–IKK binding and whether IKIP competes for the same NEMO-binding site is unknown
   • Tissue-specific regulation of IKIP expression in inflammatory contexts was not explored
3. 2022 Medium

   Discovery that IKBIP directly binds CDK4 and protects it from ubiquitin-mediated degradation revealed a second, NF-κB-independent mechanism through which IKBIP promotes G1/S cell-cycle progression in glioblastoma.

   Evidence Co-IP of IKBIP–CDK4, ubiquitination assay, IKBIP knockdown causing G1 arrest, and in vivo xenograft suppression

   PMID:36244542

   Open questions at the time

   • The E3 ligase whose activity IKBIP antagonizes to stabilize CDK4 was not identified
   • Whether CDK4 stabilization is linked to or independent of the NF-κB inhibitory function is unresolved
   • Single-lab finding awaiting independent confirmation
4. 2024 Medium

   Linking IKBIP to THBS1/FAK suppression and AKT activation expanded its oncogenic signaling repertoire and revealed context-dependent effects: IKBIP promotes tumor growth but suppresses invasion in glioblastoma while promoting both proliferation and migration in esophageal carcinoma.

   Evidence Transcriptomic profiling plus transwell/wound-healing assays in GBM cells (THBS1/FAK); IKBIP KD/OE with AKT phosphorylation readout and LY-294002 rescue in ESCC cells; both with xenograft models

   PMID:38914958 PMID:38948026

   Open questions at the time

   • Direct binding partners mediating AKT activation by IKBIP are unknown
   • Mechanism by which IKBIP downregulates THBS1 mRNA is not defined
   • Each pathway was characterized in a single tumor type by a single lab
5. 2026 Medium

   Identification of SP1 as a transcriptional driver of IKBIP and of Wnt/β-catenin/EMT as a downstream effector pathway established a transcriptional circuit (SP1→IKBIP→β-catenin stabilization→EMT) operative in glioma.

   Evidence ChIP demonstrating SP1 binding to IKBIP promoter, IKBIP KD/OE in glioma lines with Western blot for β-catenin/p-β-catenin/ZEB1/ZEB2/N-cadherin/E-cadherin, invasion assays, in vivo model

   PMID:42004064

   Open questions at the time

   • How IKBIP reduces β-catenin phosphorylation—whether by direct interaction with destruction complex components—is unknown
   • Relationship between the Wnt/β-catenin and NF-κB regulatory functions of IKBIP is unexplored
   • Single-lab finding in glioma cell lines

• A unifying model integrating IKBIP's NF-κB inhibitory, CDK4-stabilizing, AKT-activating, and Wnt/β-catenin-activating functions—and whether these reflect independent or interconnected mechanisms—remains to be established.
• No structural information exists for IKBIP or its complexes with IKKα/β or CDK4
• Tissue-specific and stimulus-specific expression regulation beyond p53 and SP1 is uncharacterized
• Whether IKBIP's proapoptotic activity in normal cells and pro-proliferative activity in cancer cells reflect the same or distinct molecular interactions is unresolved